[Treatment of childhood dystonia].
Dystonia is not uncommon in childhood, but is clinically very heterogeneous. Therefore, introduction and follow-up of the treatment of dystonia in children are often a challenge for the physicians. Progresses in functional neurosurgery have open new fields in the treatment of dystonia in children, but it should be managed by a multidisciplinary team. This paper reviews the various therapeutic options available for childhood-onset dystonia, with a specific attention to dosage and side effects of the drugs regarding pediatric population according to the data of the literature. The rational strategy for therapeutic management of the various types of childhood dystonia is discussed.
Roubertie
A
A
Service de neuropédiatrie, CHU de Montpellier, hôpital Gui-de-Chauliac, 80, avenue Fliche, 34295 Montpellier cedex 5, France. a-roubertie@chu-montpellier.fr
Roze
E
E
Bahi-Buisson
N
N
Payet
C
C
Echenne
B
B
Doummar
D
D
D000465:Algorithms; D000927:Anticonvulsants / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D002648:Child; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D003299:Cooperative Behavior; D003620:Dantrolene / Q000627:therapeutic use; D046690:Deep Brain Stimulation; D015259:Dopamine Agents / Q000627:therapeutic use; D020821:Dystonic Disorders / Q000209:etiology / Q000628:therapy*; D006801:Humans; D033183:Interdisciplinary Communication; D007980:Levodopa / Q000627:therapeutic use; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D010348:Patient Care Team; D011379:Prognosis
D000927:Anticonvulsants; D018680:Cholinergic Antagonists; D015259:Dopamine Agents; D009125:Muscle Relaxants, Central; D001569:Benzodiazepines; D007980:Levodopa; D019274:Botulinum Toxins, Type A; D003620:Dantrolene